Training intensity: fInal training session (% baseline peak work capacity) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Physiological outcomes: isoload blood lactate (mmol/L) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality, all‐cause · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in mortality, all‐cause (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality, due to pneumonia · patients with chronic obstructive pulmonary disease
It is very uncertain whether the intervention changes mortality, due to pneumonia (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (moderate certainty).
1 finding from 1 review
Intervention not reported
All pneumonia events · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in all pneumonia events (moderate certainty).
1 finding from 1 review
Intervention not reported
Withdrawals · patients with chronic obstructive pulmonary disease
The intervention leads to lower withdrawals (high certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse pneumonia events (requiring hospital admission) · patients with chronic obstructive pulmonary disease
The intervention leads to higher non‐fatal, serious adverse pneumonia events (requiring hospital… (high certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in mortality, all‐cause (high certainty).
1 finding from 1 review
Intervention not reported
Mortality, due to pneumonia · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in mortality, due to pneumonia (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (high certainty).
1 finding from 1 review
Intervention not reported
All pneumonia events · patients with chronic obstructive pulmonary disease
The intervention probably leads to higher all pneumonia events (moderate certainty).
1 finding from 1 review
Intervention not reported
Withdrawals · patients with chronic obstructive pulmonary disease
The intervention leads to lower withdrawals (high certainty).
1 finding from 1 review
Intervention not reported
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐fatal, serious adverse pneumonia events (requiring hospital admission) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse pneumonia events (requiring hospital… (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes hospital admissions due to exacerbations compared with tiotropium (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review